Therapeutic manipulation of myosin can abate the effects of MYBPC3 mutations in hypertrophic cardiomyopathy.
Should not change HCM practice; leaves open myosin modulation for MYBPC3 mutations pending human trials.
Mutations in MYBPC3 disrupt myosin states of relaxation, and manipulating myosin therapeutically abates the effects of MYBPC3 mutations.
No takes yet. Share an insight, caveat, or question.
Toepfer et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: